Year: 2022
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colo
IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer
Positive results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy, demons
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
KEYTRUDA Significantly Improved Overall Survival (OS) in Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
Inflammation Protein Contributes to Anemia of Chronic Disease by Preventing Red Blood Cell Formation
MANHASSET, N.Y., January 18, 2022–More than one billion people worldwide suffer from anemia of inflammation or anemia of chronic diseases (ACD) – and for the first time we may know why. New research from The Feinstein Institutes for Medical Research, …
Health calendar: Jan. 18, 2022
Bioidentical Hormones Market Report Progression Status and Viewpoint by 2025; Key Players
In Arkansas, Trans Teens Await an Uncertain Future
Even as the medical community grapples with how best to provide care to transgender adolescents, some states seek to ban it outright.
In Arkansas, Trans Teens Await an Uncertain Future
Even as the medical community grapples with how best to provide care to transgender adolescents, some states seek to ban it outright.
Keto and menopause: Is it a good diet for hormones?
The ketogenic diet may help with menopause-related weight gain, but there is a lack of research. Learn more about keto and menopause here.